Should We Use DARA Up Front As First-Line Therapy in MM?

Speciality: Hematology

Description:

A warm welcome to all the medical professionals in this crucial session asking the question: Should We Use DARA Up Front As First-Line Therapy in MM? The treatment landscape for multiple myeloma (MM) is rapidly evolving, and the introduction of powerful monoclonal antibodies like daratumumab (DARA) has fundamentally changed how we approach therapy. The core question now is whether to integrate DARA into the very first line of treatment for newly diagnosed multiple myeloma (NDMM) patients, and what the evidence says about this strategy.

The shift toward using DARA as part of frontline therapy is supported by robust clinical trial data. Studies such as the MAIA trial (for transplant-ineligible patients) and the GRIFFIN trial (for transplant-eligible patients) have demonstrated that adding DARA to standard regimens significantly improves the depth of response, including higher rates of complete remission and, crucially, minimal residual disease (MRD) negativity. Achieving MRD negativity is a powerful predictor of long-term, progression-free survival, and the use of DARA upfront has been shown to increase the chances of reaching this deep state of remission.

Therefore, get an overall knowledge of the evidence supporting the use of daratumumab as a frontline therapy in multiple myeloma. Listen to the webinar, grab the shared knowledge on this practice-changing data, and follow Hidoc for more such indispensable sessions that are driving oncology forward.

See More Webinars @ Hidoc Webinars